Webinar: Regulatory Medicines

Enforcement sharpens

Australia's $15 billion prescription medicines market and larger over-the-counter sector operate under the Therapeutic Goods Act 1989, with the TGA as the sole national gatekeeper for safety, quality and efficacy. The January 2026 shift to proactive, intelligence-led enforcement marks the first full-year implementation of quarterly priority reviews, moving beyond annual lists to rapid response on emerging risks such as AI-generated misinformation and influencer promotions.

Priority medicines now include erectile-dysfunction treatments, melatonin products, weight-loss injections and listed complementary medicines whose advertising claims frequently breach rules. Sponsors and importers face heightened monitoring of e-commerce and social-media channels, where substandard or falsified goods have surged since the pandemic. Non-compliance triggers graduated sanctions from warnings to infringement notices, product seizures and civil penalties that can reach hundreds of thousands of dollars per breach.

Labelling reforms add concrete deadlines: Therapeutic Goods Orders 91 and 92 automatically revoke in October 2026, forcing every sponsor to revise labels for clearer substance declarations and updated safety warnings. The changes aim to reduce exemptions while aligning with international practice, yet they impose one-time redesign and reprinting costs across thousands of stock-keeping units.

At state level, NSW's new framework will modernise scheduling, authority requirements and penalties for supply of scheduled medicines, with February 2026 consultations already signalling tighter oversight of cosmetic injectables. Pharmacies, wholesalers and prescribers in Australia's most populous state must prepare systems and training before proclamation, creating parallel compliance workstreams alongside federal obligations.

The non-obvious tension lies in balancing tighter controls against continued access: stricter advertising rules may curb misleading weight-loss claims popular amid the obesity epidemic, yet overly cautious enforcement risks slowing legitimate telehealth channels or inflating costs for smaller sponsors of listed medicines.